KisoJi Biotechnology Inc.

Remiges joined the Series A1 financing for KisoJi Biotechnologies Inc. a Canada-based biotechnology company focusing to develop oncology therapeutic agents based on its proprietary single-domain antibodies technology platform.

The proceeds from the investment will be used to finance the development of the company's platform technology as well as in-house programs.